Send us Fan MailThe hosts discuss developments in the DEA marijuana rescheduling process, noting final briefs were due Monday and the DEA is now arguing marijuana should not remain in Schedule I, acknowledging accepted medical use for pain, anorexia, and chemotherapy-related nausea, and disputing two Schedule I prongs including safety under medical supervision. They describe a waiting period after transcript-verbatim corrections and predict movement before the midterms, arguing HHS scientific findings are binding and appeals by groups like SAM and NASTA are unlikely to succeed. They emphasize rescheduling is not legalization and call for federal standards, including a “full spectrum CBD” definition and consistent THC regulation across hemp and cannabis to end “scheduled twice” confusion and address interstate-commerce limits. Other topics include lawmakers pressing the Trump administration on rollout, Georgia regulators’ limits on directing carriers, hemp farmers facing possible THC bans, market chatter on THC beverages, a dementia THC-oil trial, and a Massachusetts whistleblower lawsuit.Support the showGet our newsletter: https://bit.ly/3VEn9vu

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related